Your browser doesn't support javascript.
loading
Reproducing human and cross-species drug toxicities using a Liver-Chip.
Jang, Kyung-Jin; Otieno, Monicah A; Ronxhi, Janey; Lim, Heng-Keang; Ewart, Lorna; Kodella, Konstantia R; Petropolis, Debora B; Kulkarni, Gauri; Rubins, Jonathan E; Conegliano, David; Nawroth, Janna; Simic, Damir; Lam, Wing; Singer, Monica; Barale, Erio; Singh, Bhanu; Sonee, Manisha; Streeter, Anthony J; Manthey, Carl; Jones, Barry; Srivastava, Abhishek; Andersson, Linda C; Williams, Dominic; Park, Hyoungshin; Barrile, Riccardo; Sliz, Josiah; Herland, Anna; Haney, Suzzette; Karalis, Katia; Ingber, Donald E; Hamilton, Geraldine A.
Afiliação
  • Jang KJ; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Otieno MA; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA. geraldine.hamilton@emulatebio.com motieno@its.jnj.com.
  • Ronxhi J; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Lim HK; Janssen Pharmaceutical Research and Development, Drug Metabolism and Pharmacokinetics, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Ewart L; Clinical Pharmacology and Safety Sciences Department, Biopharmaceuticals Science Unit, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Kodella KR; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Petropolis DB; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Kulkarni G; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Rubins JE; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Conegliano D; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Nawroth J; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Simic D; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Lam W; Janssen Pharmaceutical Research and Development, Drug Metabolism and Pharmacokinetics, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Singer M; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Barale E; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Singh B; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Sonee M; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Streeter AJ; Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Manthey C; Janssen Pharmaceutical Research and Development, IPD Biology, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
  • Jones B; Clinical Pharmacology and Safety Sciences Department, Biopharmaceuticals Science Unit, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Srivastava A; Clinical Pharmacology and Safety Sciences Department, Biopharmaceuticals Science Unit, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Andersson LC; Clinical Pharmacology and Safety Sciences Department, Biopharmaceuticals Science Unit, AstraZeneca, Gothenburg SE-431 83, Sweden.
  • Williams D; Clinical Pharmacology and Safety Sciences Department, Biopharmaceuticals Science Unit, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Park H; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Barrile R; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Sliz J; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Herland A; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USA.
  • Haney S; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Karalis K; Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
  • Ingber DE; Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USA.
  • Hamilton GA; Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Sci Transl Med ; 11(517)2019 11 06.
Article em En | MEDLINE | ID: mdl-31694927
ABSTRACT
Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate drugs may produce discordant results or fail to predict complications in humans, contributing to drug failures in the clinic. Here, we applied microengineered Organs-on-Chips technology to design a rat, dog, and human Liver-Chip containing species-specific primary hepatocytes interfaced with liver sinusoidal endothelial cells, with or without Kupffer cells and hepatic stellate cells, cultured under physiological fluid flow. The Liver-Chip detected diverse phenotypes of liver toxicity, including hepatocellular injury, steatosis, cholestasis, and fibrosis, and species-specific toxicities when treated with tool compounds. A multispecies Liver-Chip may provide a useful platform for prediction of liver toxicity and inform human relevance of liver toxicities detected in animal studies to better determine safety and human risk.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Dispositivos Lab-On-A-Chip / Fígado Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Dispositivos Lab-On-A-Chip / Fígado Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos